We'd appreciate your feedback. Send feedback
Subscribe to our newsletters and alerts
Globally, gastric cancer ranks seventh in terms of incidence. A proto-oncogene that plays an important role in the pathophysiology of several human malignancies, such as gastric cancer, is HER2/neu. The introduction of trastuzumab has improved overall survival for gastric cancer that is HER2/neu-positive, locally advanced, and metastatic. To investigate the expression of HER2/neu in various histological types of stomach cancers and to establish the relationship between it and clinicopathological characteristics. 80 cases of gastric adenocarcinoma that were surgically removed between July 2016 and June 2019 were selected for the study. HER2/neu overexpression was detected in all tumor samples and was associated with several clinicopathological characteristics. In our study, the mean age of the patients was 59 years. The majority of the tumors (60%) were located in the pyloric antrum area. Intestinal type accounted for 66% of cases, followed by diffuse (29%) and mixed (5%). HER2/neu overexpression was detected in 9% of patients. There was no significant association between HER2/neu overexpression and age, gender, location, histological type, or tumor grade. No statistically significant association was found between HER2/neu expression and tumor differentiation, age, gender, tumor location, or histological type. Therefore, it may be said that HER2/neu has no bearing on prognosis in gastric cancer.
